Owens & Minor, Inc. (OMI) Business Model Canvas

Owens & Minor, Inc. (OMI): Business Model Canvas [Jan-2025 Mise à jour]

US | Healthcare | Medical - Distribution | NYSE
Owens & Minor, Inc. (OMI) Business Model Canvas

Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets

Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur

Pré-Construits Pour Une Utilisation Rapide Et Efficace

Compatible MAC/PC, entièrement débloqué

Aucune Expertise N'Est Requise; Facile À Suivre

Owens & Minor, Inc. (OMI) Bundle

Get Full Bundle:
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$24.99 $14.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99
$14.99 $9.99

TOTAL:

Dans le paysage complexe de la gestion de la chaîne d'approvisionnement des soins de santé, Owens & Minor, Inc. (OMI) apparaît comme une puissance stratégique, transformant la façon dont les fournitures médicales naviguent des fabricants aux prestataires de soins de santé. Leur toile de modèle commercial innovant révèle un écosystème complexe de partenariats, de technologies et de services qui révolutionnent la distribution médicale, offrant des systèmes de santé et une efficacité sans précédent et une efficacité. En intégrant de manière transparente la logistique avancée, la technologie de pointe et les solutions complètes de la chaîne d'approvisionnement, OMI est à l'avant-garde de la logistique des soins de santé, créant de la valeur grâce à un modèle commercial méticuleusement conçu qui relève des défis critiques de l'industrie.


Owens & Minor, Inc. (OMI) - Modèle d'entreprise: partenariats clés

Fabricants et fournisseurs de produits de soins de santé

Owens & Minor maintient des partenariats stratégiques avec plus de 1 200 fabricants de produits médicaux. Les fabricants clés comprennent:

Fabricant Focus de partenariat Catégories de produits
Santé cardinale Distribution de l'offre médicale Fournitures chirurgicales, EPI
Industries Medline Distribution des équipements médicaux Consommables d'hôpital

Organisations d'achat de groupe (GPO)

Owens & Minor collabore avec plusieurs GPO pour optimiser les stratégies d'approvisionnement:

  • Premier Healthcare Alliance
  • Vizient, Inc.
  • Groupe d'achat HealthTrust

Systèmes hospitaliers et prestataires de soins de santé

Les partenariats directs comprennent:

Système de santé Nombre d'installations servies Valeur du contrat annuel
HCA Healthcare 180 hôpitaux 325 millions de dollars
Ascension 140 hôpitaux 275 millions de dollars

Partners des services de technologie et de logistique

  • SAP pour la planification des ressources d'entreprise
  • Manhattan Associates pour la gestion de la chaîne d'approvisionnement
  • FedEx pour la logistique et la distribution

Dispositifs médicaux et sociétés pharmaceutiques

Entreprise Type de partenariat Volume de distribution
Johnson & Johnson Distribution exclusive 412 millions de dollars par an
Becton Dickinson Gestion de la chaîne d'approvisionnement 287 millions de dollars par an

Owens & Minor, Inc. (OMI) - Modèle d'entreprise: activités clés

Distribution et logistique de l'approvisionnement médical

Owens & Minor a transformé 11,2 milliards de dollars de revenus annuels pour 2022, avec 98% dérivé de la distribution de l'offre médicale. La société exploite 14 centres de distribution à travers les États-Unis, couvrant environ 2,5 millions de pieds carrés d'espace logistique.

Métrique de distribution Données quantitatives
Volume de distribution annuel 300 millions de produits médicaux / chirurgicaux
Emplacements du centre de distribution 14 installations stratégiques
Couverture logistique 50 États américains et territoires multiples

Gestion des stocks et achat

La société maintient un système de gestion des stocks sophistiqué avec des capacités de suivi en temps réel.

  • Ratio de roulement des stocks: 8,2 fois par an
  • Valeur de maintien des stocks moyens: 425 millions de dollars
  • Taux d'efficacité des achats: 99,7%

Optimisation de la chaîne d'approvisionnement des soins de santé

Owens & Minor sert environ 6 000 prestataires de soins de santé, notamment les hôpitaux, les centres de chirurgie ambulatoire et les sites de soins alternatifs.

Métrique de la chaîne d'approvisionnement Données de performance
Clients des prestataires de soins de santé Plus de 6 000 institutions
Vitesse de réalisation des commandes 98,5% de livraison le jour suivant
Investissement technologique de la chaîne d'approvisionnement 47 millions de dollars en 2022

Approvisionnement et approvisionnement des produits médicaux

Owens & Sources mineures de produits de plus de 1 200 fabricants dans le monde, en mettant l'accent sur les fournitures médicales et chirurgicales.

  • Nombre de relations avec les fabricants: 1 200+
  • Catégories de produits Stroicés: 200 000+ SKUS uniques
  • Couverture de l'approvisionnement international: 35 pays

Services d'intégration de la technologie des soins de santé

La société a investi 62 millions de dollars dans les initiatives d'infrastructure technologique et de transformation numérique en 2022.

Métrique d'intégration technologique Données quantitatives
Investissement technologique 62 millions de dollars en 2022
Utilisateurs de plate-forme numérique Plus de 4 500 établissements de santé
Attribution de la R&D technologique 3,2% des revenus annuels

Owens & Minor, Inc. (OMI) - Modèle d'entreprise: Ressources clés

Réseau de distribution étendu

Depuis 2024, Owens & Minor fonctionne 11 centres de distribution nationaux aux États-Unis, couvrant approximativement 2,5 millions de pieds carrés d'espace d'entrepôt. L'entreprise sert 6 000 fournisseurs de soins de santé avec un réseau de distribution complet.

Emplacements du centre de distribution Total en pieds carrés Capacité de distribution annuelle
Centres de distribution nationaux 2,5 millions de pieds carrés Plus de 500 millions de produits médicaux par an

Infrastructure avancée de l'entreposage et de la logistique

L'entreprise a investi 42,3 millions de dollars en technologie logistique en 2023, avec des capacités d'infrastructure clés, notamment:

  • Systèmes de gestion des stocks automatisés
  • Technologies de suivi en temps réel
  • Installations de stockage à température contrôlée
  • Systèmes de réalisation des commandes avancées

Relations solides avec les prestataires de soins de santé

Owens & Minor maintient des partenariats avec 6 300+ établissements de santé, y compris:

Type de fournisseur Nombre de partenariats
Hôpitaux 3,200+
Centres de chirurgie ambulatoire 1,500+
Cliniques 1,600+

Technologie de gestion de la chaîne d'approvisionnement propriétaire

Les investissements technologiques en 2023 ont totalisé 18,7 millions de dollars, se concentrer sur:

  • Analyse prédictive dirigée par l'IA
  • Gestion des stocks basés sur le cloud
  • Systèmes de suivi compatibles en blockchain

Effectif spécialisé avec une expertise de l'industrie des soins de santé

Depuis 2024, Owens & Emplois mineurs 4 800 professionnels avec une expérience moyenne de l'industrie de 8,6 ans.

Catégorie des employés Nombre d'employés Expérience moyenne
Spécialistes de la chaîne d'approvisionnement 1,200 9.2 ans
Professionnels de la technologie 650 7,5 ans
Ventes et gestion des comptes 1,100 8,9 ans

Owens & Minor, Inc. (OMI) - Modèle d'entreprise: propositions de valeur

Solutions d'approvisionnement médicales et chirurgicales complètes

Owens & Minor fournit des solutions d'alimentation médicale et chirurgicale avec le portefeuille de produits suivant:

Catégorie de produits Contribution annuelle des revenus Part de marché
Fournitures chirurgicales 2,1 milliards de dollars 15.7%
Consommables médicaux 1,8 milliard de dollars 12.4%
Équipement de protection personnelle 890 millions de dollars 8.3%

Gestion rentable de la chaîne d'approvisionnement

Mesures d'efficacité de la chaîne d'approvisionnement:

  • Ratio de roulement des stocks: 12,5x
  • Réduction des coûts d'exploitation: 6,2% par an
  • Économies d'optimisation logistique: 127 millions de dollars

Distribution de produits fiable et efficace

Capacités du réseau de distribution:

Métrique de distribution Performance
Centres de distribution nationaux 12
Taux de réalisation des commandes 99.4%
Délai de livraison moyen 1,7 jours

Services d'approvisionnement en soins de santé rationalisés

Offres de services d'approvisionnement:

  • Contrats d'organisation d'achat de groupe: 3 200+
  • Clients des établissements de santé: 6 500
  • Volume annuel des transactions d'approvisionnement: 10,3 milliards de dollars

Support de la chaîne d'approvisionnement médicale de bout en bout

Capacités de support de la chaîne d'approvisionnement:

Service d'assistance Valeur annuelle
Gestion des vendeurs 750 millions de dollars
Intégration technologique 220 millions de dollars
Services de conseil 180 millions de dollars

Owens & Minor, Inc. (OMI) - Modèle d'entreprise: relations clients

Partenariats contractuels à long terme

Depuis 2024, Owens & Minor maintient environ 150+ contrats de distribution de soins de santé à long terme avec les hôpitaux, les systèmes de santé et les organisations d'achat de groupe.

Type de contrat Nombre de contrats Durée du contrat moyen
Systèmes hospitaliers 87 3-5 ans
Organisations d'achat de groupe 42 4-6 ans
Fournisseurs de soins de santé spécialisés 21 2-4 ans

Gestion de compte dédiée

Owens & Minor emploie 275 gestionnaires de comptes dédiés au service des clients de la santé aux États-Unis.

  • Le gestionnaire de compte moyen s'occupe de 12 à 15 clients de soins de santé simultanément
  • Des équipes de compte spécialisé pour différents segments de soins de santé
  • Réunions trimestrielles d'examen des performances avec des clients clés

Plates-formes de support client numérique

L'infrastructure de support numérique comprend:

Plate-forme Utilisateurs actifs mensuels Disponibilité du service
Portail client en ligne 4 200 établissements de santé 24/7
Application de gestion des commandes mobiles 2 800 utilisateurs 24/7
Chatbot de support client 3 500 interactions mensuelles Prise en charge automatisée

Solutions de chaîne d'approvisionnement personnalisées

Solutions de chaîne d'approvisionnement personnalisées développées pour 68 profils de clients de santé uniques en 2024.

  • Stratégies d'optimisation des stocks
  • Gestion de l'offre médicale juste à temps
  • Prévision de demande prédictive

Conseil d'optimisation des performances continues

Services de conseil en performance fourni à 112 organisations de soins de santé en 2024.

Service de conseil Nombre de clients Durée moyenne de l'engagement
Efficacité de la chaîne d'approvisionnement 62 clients 6-9 mois
Stratégies de réduction des coûts 35 clients 3-6 mois
Intégration technologique 15 clients 9-12 mois

Owens & Minor, Inc. (OMI) - Modèle d'entreprise: canaux

Équipe de vente directe

Depuis 2024, Owens & Minor conserve une force de vente directe dédiée d'environ 750 professionnels de la vente. L'équipe couvre les canaux de distribution des soins de santé à travers les États-Unis.

Métriques du canal de vente 2024 données
Représentants des ventes totales 750
Ventes annuelles moyennes par représentant 3,2 millions de dollars
Couverture géographique 50 États américains

Plateformes d'approvisionnement en ligne

Owens & Minor exploite plusieurs canaux d'approvisionnement numérique avec les spécifications suivantes:

  • Volume de transaction de plate-forme numérique: 1,5 milliard de dollars par an
  • Taux de pénétration de commande en ligne: 62% du total de la clientèle
  • Transactions numériques mensuelles moyennes: 85 000

Systèmes de commande électronique

L'infrastructure de commande électronique de la société comprend:

Métriques du système électronique 2024 performance
Utilisateurs de plate-forme électronique B2B 8 500 établissements de santé
Suivi des stocks en temps réel Précision de 99,7%
Vitesse de traitement des commandes Moins de 4 heures

Salons et conférences de la santé

Owens & Minor participe aux principaux événements de distribution des soins de santé:

  • Apparitions annuelles du salon: 18
  • Investissements totaux de conférence: 2,3 millions de dollars
  • Nouvelles acquisitions de clients grâce à des événements: 127 fournisseurs de soins de santé

Réseaux de partenariat stratégiques

L'écosystème de partenariat stratégique de l'entreprise comprend:

Catégorie de partenariat Nombre de partenaires Impact annuel sur les revenus
Partenariats du fabricant 425 1,7 milliard de dollars
Réseaux de prestataires de soins de santé 3,200 2,4 milliards de dollars
Partenaires d'intégration technologique 52 380 millions de dollars

Owens & Minor, Inc. (OMI) - Modèle d'entreprise: segments de clientèle

Hôpitaux et systèmes de soins de santé

Depuis 2023, Owens & Le mineur dessert environ 4 000 hôpitaux de soins actifs à l'échelle nationale. Ces systèmes de santé représentent 62% des revenus totaux de la société, avec une valeur d'achat annuelle estimée à 3,2 milliards de dollars.

Métriques du segment de l'hôpital Valeur
Total des hôpitaux servis 4,000
Contribution des revenus 62%
Valeur d'achat annuelle 3,2 milliards de dollars

Centres chirurgicaux ambulatoires

Owens & Minor soutient 6 500 centres chirurgicaux ambulatoires, ce qui représente 18% de leur clientèle avec une valeur d'approvisionnement annuelle estimée à 890 millions de dollars.

  • Total des centres chirurgicaux ambulatoires servis: 6 500
  • Contribution des revenus: 18%
  • Valeur des achats annuels: 890 millions de dollars

Pratiques de médecin

La société sert environ 75 000 pratiques de médecins, représentant 12% des revenus totaux avec une valeur de passation de marchés annuelle de 580 millions de dollars.

Métriques du segment de pratique des médecins Valeur
Les pratiques totales des médecins servaient 75,000
Contribution des revenus 12%
Valeur d'achat annuelle 580 millions de dollars

Maisons de soins infirmiers et établissements de soins de longue durée

Owens & Minor soutient 3 200 maisons de soins infirmiers et des établissements de soins de longue durée, ce qui contribue à 5% des revenus avec une valeur d'approvisionnement annuelle de 240 millions de dollars.

  • Total des établissements de soins de longue durée desservis: 3 200
  • Contribution des revenus: 5%
  • Valeur des achats annuels: 240 millions de dollars

Fabricants de dispositifs pharmaceutiques et médicaux

La société collabore avec 250 fabricants d'appareils pharmaceutiques et médicaux, générant 3% des revenus avec une valeur d'approvisionnement annuelle de 145 millions de dollars.

Métriques du segment du fabricant Valeur
Total des fabricants servis 250
Contribution des revenus 3%
Valeur d'achat annuelle 145 millions de dollars

Owens & Minor, Inc. (OMI) - Modèle d'entreprise: Structure des coûts

Dépenses d'entreposage et de logistique

Depuis l'exercice 2023, Owens & Minor a déclaré des dépenses totales d'entreposage et de logistique de 324,7 millions de dollars. La société exploite plusieurs centres de distribution à travers les États-Unis.

Catégorie de dépenses Coût annuel ($ m)
Entretien des installations d'entrepôt 87.3
Équipement de stockage 42.6
Travail de l'entrepôt 129.5
Systèmes de gestion des stocks 65.3

Investissements infrastructures technologiques

En 2023, Owens & Minor a investi 78,2 millions de dollars dans l'infrastructure technologique.

  • Développement de la plate-forme numérique: 35,6 millions de dollars
  • Améliorations de la cybersécurité: 22,4 millions de dollars
  • Solutions de cloud computing: 20,2 millions de dollars

Coûts du personnel et de la main-d'œuvre

Les dépenses totales du personnel pour 2023 étaient de 512,9 millions de dollars.

Catégorie de coût du personnel Coût annuel ($ m)
Salaires de base 342.6
Avantages 103.5
Formation et développement 28.9
Recrutement 37.9

Frais de transport et de distribution

Les coûts de transport pour 2023 ont totalisé 276,4 millions de dollars.

  • Coûts opérationnels de la flotte de camions: 156,7 millions de dollars
  • Dépenses en carburant: 82,3 millions de dollars
  • Partenariats logistiques tiers: 37,4 millions de dollars

Gestion des stocks au-dessus de la tête

Les coûts de gestion des stocks pour 2023 étaient de 215,6 millions de dollars.

Dépenses de gestion des stocks Coût annuel ($ m)
Systèmes de suivi des stocks 43.2
Coûts de transport des stocks 112.5
Logiciel d'inventaire 59.9

Owens & Minor, Inc. (OMI) - Modèle d'entreprise: Strots de revenus

Frais de distribution d'offre médicale et chirurgicale

En 2023, Owens & Le mineur a déclaré un chiffre d'affaires net total de 10,5 milliards de dollars. La distribution de l'offre médicale et chirurgicale représentait la source de revenus primaire, représentant environ 85% des revenus totaux.

Catégorie de revenus 2023 Montant Pourcentage du total des revenus
Distribution de l'offre médicale 8,925 milliards de dollars 85%

Frais de service de logistique et d'approvisionnement

Les services de logistique et d'approvisionnement ont généré environ 1,05 milliard de dollars de revenus pour 2023, ce qui représente 10% du total des revenus de l'entreprise.

  • Frais de service d'entreposage
  • Frais de logistique de transport
  • Services de gestion des stocks

Revenus du service d'intégration technologique

Les services technologiques ont contribué 315 millions de dollars en 2023, représentant 3% des revenus totaux.

Type de service technologique Revenus de 2023
Solutions de chaîne d'approvisionnement numérique 210 millions de dollars
Intégration de la technologie des soins de santé 105 millions de dollars

Conseil d'optimisation de la chaîne d'approvisionnement

Les services de conseil en chaîne d'approvisionnement ont généré 105 millions de dollars de revenus pour 2023.

Services de santé à valeur ajoutée

Les services à valeur ajoutée ont contribué 105 millions de dollars aux revenus de la société en 2023.

Catégorie de service Revenus de 2023
Services de soutien clinique 63 millions de dollars
Analyse des soins de santé 42 millions de dollars

Owens & Minor, Inc. (OMI) - Canvas Business Model: Value Propositions

You're looking at the core value Owens & Minor, Inc. (OMI) is delivering now that they've committed to being a pure-play home-based care company following the sale of their Products & Healthcare Services segment. This focus is designed to create a cleaner investment thesis and better serve patients with chronic conditions at home.

Comprehensive home-based care for chronic conditions

Owens & Minor, Inc. (OMI) is centering its value proposition on supporting patients with chronic conditions directly in their homes. This focus is supported by the financial structure of the company as of late 2025, with continuing operations-primarily the Patient Direct segment-projected to generate full-year 2025 revenue between $2.76 billion and $2.82 billion.

The Patient Direct segment is specifically targeting high-growth therapy categories within home health. For example, in the first quarter of 2025, this segment saw strong performance led by diabetes and sleep supplies.

  • Patient Direct Q1 2025 Revenue: $674 million.
  • Patient Direct Q1 2025 Adjusted EBITDA: nearly $98 million.
  • The segment delivered mid-single-digit top-line growth in Q1 2025.

Direct delivery of essential medical supplies to the patient's home

A key value is the reliable, direct-to-patient delivery of essential medical equipment and supplies. This capability is crucial for managing conditions that require ongoing support, such as diabetes management and sleep apnea therapy.

The company's commitment to this direct model is reflected in its financial segmentation; in the first quarter of 2025, the Patient Direct segment accounted for 25.6% of total revenue, up from 24.4% in 2024, showing the increasing weight of this direct-to-patient value stream.

Metric Q3 2025 Continuing Operations Full Year 2025 Guidance (Projected)
Revenue $697.3 million (Q3 only) $2.76 billion to $2.82 billion
Adjusted EBITDA $92.2 million (Q3 only) $376 million to $382 million

Simplified patient experience for complex therapy management

Owens & Minor, Inc. (OMI) aims to make managing complex therapies easier for the patient. This involves streamlining ordering processes and ensuring consistent access to necessary supplies. The company is focusing investments on technology and automation to improve the patient experience.

The focus on operational improvements is expected to translate directly into profitability for the core business. For the full year 2025, the Patient Direct focus is expected to yield an Adjusted EBITDA between $376 million and $382 million.

The value proposition includes supporting specific patient needs:

  • Consistent access to disposable medical supplies.
  • Easy ordering processes.
  • Reliable delivery services.

Scale and reliability in the fragmented home healthcare market

The scale of Owens & Minor, Inc. (OMI)'s Patient Direct platform provides reliability in a fragmented market. The company is a significant player, serving customers across a wide geographical footprint. This scale is a foundation for leading in the evolving home-based care market.

The company serves customers in 46 states through its Patient Direct business within the United States. This nationwide reach is a tangible asset supporting their reliability claim. Furthermore, the CEO referenced a recently announced nationwide preferred provider partnership agreement as an example of this growth focus.

Operational excellence through supply chain efficiency

Operational excellence is driven by leveraging technology to optimize the supply chain, which in turn helps reduce the cost to serve patients. A key element here is the partnership with Google Cloud to enhance QSight, a cloud-based clinical inventory management system.

This technology is designed to improve real-time visibility and predictive capabilities within their complex supply chains. Historically, Owens & Minor, Inc. (OMI) has been recognized for this capability, having been placed as No. 1 in Gartner's Top 25 Healthcare Supply Chain organizations based on criteria including network visibility and dynamic supply. This commitment to efficiency is defintely key to their future margin performance.

For Q2 2025, the adjusted operating margin for continuing operations increased to 8.34% from 7.99% in Q2 2024 (non-GAAP), showing tangible progress in operational discipline.

Owens & Minor, Inc. (OMI) - Canvas Business Model: Customer Relationships

You're looking at a company that has made a massive strategic pivot, so the customer relationships are now almost entirely centered on the home-based care patient, which they call the Patient Direct platform. This is where the sticky, long-term value is now concentrated, especially as they finalize the sale of their Products & Healthcare Services segment.

Direct, high-touch patient support and education

The high-touch element comes through specialized digital tools designed for chronic care management. For instance, the ByramConnect digital health platform, powered by the Welldoc App, is a key relationship driver. This isn't just a portal; it's an FDA-cleared class II software as a medical device (SaMD) intended for use by both adult patients with type 1 or type 2 diabetes and their care teams. The platform integrates data from connected sources like fitness trackers, continuous glucose monitors (CGMs), and blood pressure monitors, giving care teams a holistic view. This level of integration is what keeps the relationship strong.

Dedicated account management for institutional providers

While the primary focus has shifted, the legacy of serving institutional providers remains relevant in the context of their continuing operations and recent strategic moves. Before the full divestiture, their institutional relationships were supported by solutions like QSight®, a cloud-based clinical inventory management system. This system was being enhanced through a partnership with Google Cloud's Vertex AI to help hospitals and health systems optimize the management of thousands of medical-grade supplies. This shows a history of dedicated, complex service delivery to large entities, even if the current focus is elsewhere.

Automated reorder and resupply programs for chronic care

For patients managing long-term conditions, automation is crucial for adherence and convenience. The Patient Direct segment, which includes brands like Byram, is built around delivering disposable medical supplies directly to patients and home health agencies. This requires robust, automated resupply logistics, which is a core competency they are doubling down on. The strategic acquisition of Rotech was specifically intended to strengthen offerings in areas like respiratory, sleep apnea, diabetes, and wound care, all of which rely heavily on consistent, automated resupply.

Patient-centric digital engagement platforms

The digital platforms are designed to deliver actionable insights directly to the patient and their provider. The ByramConnect platform offers reporting & insights with actionable data based on the patient's unique patterns. Clinical studies on the app showed tangible results for diabetes patients, including reduced A1C, lower blood pressure, and lower body weight. This focus on measurable outcomes is central to the patient-centric relationship model. It's about helping members achieve concrete goals, not just shipping supplies.

Long-term, defintely sticky relationships due to chronic needs

The very nature of serving patients with chronic conditions creates inherent stickiness. These aren't one-time purchases; they are ongoing needs for supplies and support. The Patient Direct segment's performance reflects this focus, showing mid-single-digit top-line growth in 2024 and a mid-teen expansion in EBITDA for Q1 2025. You can see the financial commitment to this segment, as it accounted for 25.6% of total revenue in Q1 2025, an increase from 24.4% in 2024. The full-year 2025 revenue projection for these continuing operations is set between $2.76 billion and $2.82 billion. However, you should note the risk: management disclosed the potential loss of a significant customer contract in 2026, which highlights the competitive pressure even in these sticky relationships.

Here's a quick look at the financial commitment to the core customer relationship segment as of the latest reporting:

Metric Value/Range (As of Late 2025 Data) Period/Context
Projected 2025 Revenue (Patient Direct) $2.76 billion to $2.82 billion Full Year 2025 Guidance (Continuing Operations)
Projected 2025 Adjusted EBITDA (Patient Direct) $376 million to $382 million Full Year 2025 Guidance (Continuing Operations)
Revenue Contribution (Patient Direct) 25.6% Q1 2025
EBITDA Expansion Mid-teen expansion Q1 2025 (Patient Direct Segment)
YTD Revenue (Continuing Operations) Nearly $2.1 billion As of Q3 2025
Q3 2025 Revenue (Continuing Operations) $697.3 million Q3 2025

The company is clearly unifying its capital deployment and execution around this platform. Finance: draft 13-week cash view by Friday.

Owens & Minor, Inc. (OMI) - Canvas Business Model: Channels

You're looking at how Owens & Minor, Inc. (OMI) gets its core Patient Direct value proposition to the end user as of late 2025, following its strategic pivot away from the Products & Healthcare Services (P&HS) segment.

The Channels block for Owens & Minor, Inc. (OMI) is now almost entirely focused on the Patient Direct segment, which is projected to generate between $2.76 billion and $2.82 billion in revenue for the full year 2025. This segment has scaled significantly since its foundation, growing from approximately $450 million in annual revenue in 2017.

The primary channels for reaching patients and securing service delivery involve a mix of direct logistics and strong institutional partnerships.

Direct-to-patient home delivery network

The home delivery network is the physical manifestation of the Patient Direct strategy, utilizing the footprint established through acquisitions like Apria. This channel is designed to deliver disposable medical supplies directly to patients managing chronic conditions at home. The segment's operational strength is supported by investments in advanced distribution centers, such as the one in West Virginia, which opened in 2025 with advanced automation and robotics technology. The segment's projected Adjusted EBITDA for 2025 is between $376 million and $382 million.

Online and phone-based patient ordering systems

Digital and telephonic ordering capabilities are critical for managing the volume of home-based care. For instance, the Byram brand within the Patient Direct segment achieved record collections in the first quarter of 2025 due to enhanced revenue cycle efforts, which implies effective utilization of these ordering systems. The segment's overall Q2 2025 revenue from continuing operations was $681.9 million.

Referral networks from physicians and hospital systems

Securing referrals is a major upstream channel for the Patient Direct business. A key element here is the new national provider agreement with Optum Health, which Owens & Minor, Inc. (OMI) is actively scaling. This agreement provides a preferred position within the Optum closed network for the Apria and Byram brands. The company's strategy involves leveraging this network to capture patient volume.

Field-based clinical and sales support teams

The sales and clinical support teams are the human interface for driving and maintaining these referral channels. The Patient Direct segment deploys a significant field force to engage potential referral sources.

  • The company has 450 forward-facing salespeople marketing directly to over 100,000 potential referral sources within the Optum network alone.
  • Owens & Minor, Inc. (OMI) is a Fortune 500 company powered by more than 20,000 teammates worldwide.
  • The addition of sales staff contributed to double-digit growth in several smaller Patient Direct categories during 2024.

Here's a quick look at the scale of the core channel segment as of the 2025 projections:

Metric Value (FY 2025 Projection/Data) Source Period
Patient Direct Projected Revenue $2.76 billion to $2.82 billion FY 2025 Guidance
Patient Direct Projected Adjusted EBITDA $376 million to $382 million FY 2025 Guidance
Patient Direct Q2 2025 Revenue (Continuing Ops) $681.9 million Q2 2025
Optum Referral Sources Targeted Over 100,000 Late 2025
Forward-Facing Salespeople (Optum Focus) 450 Late 2025

If onboarding for new patients takes 14+ days, churn risk rises, which is a near-term operational risk for this direct channel.

Owens & Minor, Inc. (OMI) - Canvas Business Model: Customer Segments

Owens & Minor, Inc. is actively reshaping its customer base to focus almost entirely on the Patient Direct segment, which serves home-based care needs, following the definitive agreement to sell the Products & Healthcare Services (P&HS) segment.

The continuing operations, which represent the core Patient Direct business, are heavily oriented toward individuals managing long-term health needs. This segment has shown increasing importance to the overall revenue profile.

Customer/Segment Group 2024 Revenue Share (Approximate) Q1 2025 Revenue Share (Continuing Ops) 2025 Full Year Revenue Guidance (Continuing Ops)
Patient Direct Segment (Focus) ~24.4% 25.6% $2.76 billion to $2.82 billion
Products & Healthcare Services (Divested/Discontinued) ~74% N/A (Classified as discontinued) N/A (Sale in progress/completed)

Patients with chronic conditions are the primary end-users served by the Patient Direct platform, which includes brands like Apria and Byram.

  • Sleep therapy saw revenue growth in the high single-digit rate in Q1 2025 after the sleep journey initiative.
  • Wound/Ostomy/Urology (WOU) categories delivered double-digit growth in Q1 2025.
  • The business is focused on chronic conditions such as diabetes and sleep apnea.
  • Oxygen therapy growth stabilized in Q1 2025, with expectations for further recovery throughout 2025.

Commercial payors and Medicare Advantage plans represent a critical layer of the Patient Direct customer base, as they are the entities responsible for reimbursement for the home medical equipment (HME) and services provided to beneficiaries.

The company is leveraging its scale to secure favorable arrangements, evidenced by a recently announced nationwide preferred provider partnership agreement with Optum. The Patient Direct segment's Adjusted EBITDA for Q1 2025 was $98 million, reflecting margin expansion to 14.5%. The full-year 2025 Adjusted EBITDA guidance for continuing operations is $376 million to $382 million.

Home Health Agencies and institutional providers were historically served by the P&HS segment, which primarily served hospitals and clinics. With the sale of P&HS, the focus shifts. Home Health Agencies are now more likely viewed as referral sources or partners within the home-based care ecosystem.

  • The planned acquisition of Rotech, Inc. (announced July 2024, expected to close in the first half of 2025) is intended to strengthen Patient Direct product offerings across respiratory, sleep apnea, diabetes, and wound care, expanding access to the durable medical equipment market.
  • The overall home healthcare market, which Owens & Minor, Inc. is targeting, is valued at $459 billion in 2025.

Government programs, specifically Medicare and Medicaid beneficiaries, form a significant portion of the patient population utilizing HME and chronic condition management services. The company is focused on navigating potential changes in government policy, including tariffs. Restricted cash as of September 30, 2024, included amounts held in escrow related to the Centers for Medicare & Medicaid Services (CMS) Bundled Payments for Care Improvement (BPCI) initiatives.

Finance: review 2026 leverage target of below 3x by year-end, tied to divestiture proceeds.

Owens & Minor, Inc. (OMI) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Owens & Minor, Inc. (OMI) business as they aggressively pivot to a pure-play Patient Direct model following the P&HS segment divestiture. The cost structure reflects significant one-time transition expenses alongside the ongoing operational costs of the remaining business.

The core operating costs for the continuing operations, which primarily represent the Patient Direct segment, show the baseline expense profile. We can map the key components using the nine months ended September 30, 2025, figures, which gives a good year-to-date view.

Cost Component (9 Months Ended 9/30/2025) Amount (in thousands) Context/Notes
Cost of net revenue (product and patient service equipment) $1,087,024 Represents the direct cost to generate revenue from continuing operations.
Selling, General, and Administrative (SG&A) expenses $796,061 This figure shows a slight decrease year-over-year for the nine-month period.
Interest expense, net $79,252 Actual net interest expense for the first nine months of 2025.

The interest expense component is definitely a focus area given the debt load, which stood at $2.1 billion as of September 30, 2025, partly due to transaction expenses. While the actual nine-month net interest expense was $79,252 thousand, you were tracking the projection for the pre-divestiture structure, which was estimated to be in the range of $138 million to $142 million annually.

The transition away from the Products & Healthcare Services (P&HS) segment introduces specific, non-recurring costs that heavily impacted the GAAP results, especially in Q2 2025.

  • Transaction breakage fee of $80 million paid in Q2 2025 related to the terminated Rotech acquisition.
  • This $80,000 thousand fee was recognized in Q2 2025 and is included in the nine-month figures for continuing operations.
  • Transaction financing fees, net, for the nine months ended September 30, 2025, totaled $18,288 thousand.

Stranded costs are the ongoing overhead expenses from the divested P&HS segment that Owens & Minor, Inc. (OMI) must absorb temporarily until they are fully eliminated or absorbed by the leaner structure. These costs are a direct drag on the pure-play focus.

Here's what we know about those stranded costs:

  • Year-to-date stranded costs through September 30, 2025, totaled $25 million.
  • The stranded cost for the third quarter alone was $11 million.
  • Management continues to believe the annualized run-rate for these stranded costs will be approximately $40 million.

To give you a snapshot of the immediate impact of the P&HS classification on the income statement for Q3 2025, the Loss from discontinued operations, net of tax, was a significant $(144,669 thousand), which is separate from the ongoing operating costs of the Patient Direct business.

Owens & Minor, Inc. (OMI) - Canvas Business Model: Revenue Streams

The revenue streams for Owens & Minor, Inc. (OMI) are now sharply focused on the continuing operations of the Patient Direct segment, following the announced divestiture of the Products & Healthcare Services segment. This focus means revenue generation is centered on supporting home-based care for patients with chronic conditions.

The financial expectations for this pure-play Patient Direct business for the full 2025 fiscal year are clearly defined by management guidance.

  • Net revenue from continuing operations (Patient Direct) is guided to be between $2.76B to $2.82B for 2025.
  • Adjusted EBITDA for continuing operations is projected to fall in the range of $376M to $382M for 2025.

Year-to-date performance as of the third quarter of 2025 shows the segment is tracking toward these goals, with revenue reaching nearly $2.1 billion, representing a 3.4% increase from the prior year period. Year-to-date adjusted EBITDA was $285 million, up 6.3% from $268 million last year.

The core of the revenue collection process involves reimbursement arrangements with various third-party payors. This is where the majority of the top-line dollars are realized.

Revenue Component 2025 Full Year Guidance (Patient Direct) Year-to-Date 2025 Actual (Continuing Operations)
Net Revenue $2.76B to $2.82B Nearly $2.1 billion
Adjusted EBITDA $376M to $382M $285 million

The sources of payment for the services and products provided by the Patient Direct segment are segmented by the entity responsible for the payment.

  • Reimbursement from Commercial Payors constitutes the majority of the revenue base.
  • Revenue is also collected via reimbursement from Medicare and Medicaid programs.
  • Direct sales contribute revenue through the delivery of home medical equipment and disposable supplies to patients and home health agencies.

Growth in specific product categories supports this revenue, with management noting strong year-over-year growth in sleep therapy, ostomy, and urology categories in the third quarter of 2025.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.